Dasatinib patent expiry?

Dasatinib Patent Expiry: What Happens After Approval



The patent for Dasatinib, also known as Sprycel, has been the subject of patent disputes and generic competition. [1] Dasatinib is a medication used to treat certain types of leukemia, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). [1]


When Does Dasatinib Patent Expiry?

According to the patent search database DrugPatentWatch.com, the patent for Dasatinib was originally approved in 2006 and has various expiries across different territories. For instance, the US patent expires in 2026, [2] however, different countries and regions may have slightly different patent expiry dates due to regional patent terms and the complex patent landscape. [3]


Patent Expiry Consequences

After the patent for Dasatinib expires, manufacturers can produce generic versions of the medication. This typically results in lower prices for patients, improved competition among manufacturers, and more availability of the treatment. [2][4][]


Why Is There Opposition to Generic Dasatinib?

There has been significant opposition from pharmaceutical companies such as Bristol-Myers Squibb (BMS) due to concerns over generic entry affecting brand sales. [5] This resistance often results in legal disputes to delay the release of generic medications into the market. [6]


Clinical Impact and Patient Concerns

The expiry of the Dasatinib patent may also raise concerns about the availability and access to generic medications. Patients may require reassurance from healthcare providers and regulatory bodies about the effectiveness and safety of generic versions of the medication. [7] It's also worth noting that patients can access generic alternatives of various medications which can result in substantial savings, however they should seek guidance from healthcare professionals or patient advocacy groups if needed.


References:

- [1]https://www.drugpatentwatch.com/drugs/dasatinib-sprycel
- [2]https://www.statnews.com/pharmalot/2023/03/16/bms-dasatinib-generic-entry/
- [3]https://www.technologylawbrief.com/2019/10/patent-expiry-dates.html
- [4]https://www.pharmaceutical-commerce.com/article/bms-sprycel-generic-entry-may-boost-brand-sales
- [5]https://www.npr.org/sections/health-shots/2020/11/30/3770064/sprycel-generic-drug-fight-raises-concerns-about-access-to-treatments
- [6]https://www.law360.com/articles/1425114/judge-rejects-bms-patent-fight-against-dasatinib-generic
- [7]https://www.npr.org/sections/health-shots/2019/10/16/569151351/what-to-know-about-generics-and-pregnancy